It is very essential for virus diagnosis and therapy to discover effective and specific biomolecular targeting virus. Anti-Virus Biomolecular Discovery, a powerful platform for the development of anti-virus biomolecular, has been successfully established in Creative Biolabs. Based on our cutting-edge platforms, we offer high-quality services for the discovery and development of functional antibodies/peptides and diagnostic tools for highly pathogenic avian influenza (HPAI).
HPAI A H5N1 influenza virus—the name indicates that this bird virus carries type 5 hemagglutinin and type 1 neuraminidase, the two major flu antigens. H5N1, which rapidly kills infected birds, is now present in flocks around the world and, since 1997, it has caused 258 cases of human flu and 153 deaths. Human infections with H5N1 are caused through close contact with infected birds but, luckily, H5N1 rarely passes between humans. H5N1 might acquire the ability to move between humans and start a human influenza pandemic at any time. Some of the H5N1 viruses are resistant to the antiviral drugs used to treat flu and there will inevitably be a lag of some months between the emergence of a human pandemic H5N1 strain and the bulk production of a vaccine effective against it. Thus, new diagnosis and therapeutic strategies are needed to combat human infections with H5N1.
The development of neutralizing antibody for H5N1 viruses has been impeded by its apparent poor immunogenicity. In addition, the bio-safety concerns arise for the production of viruses required for conventional inactivated and live attenuated vaccines that would have potential risks of genetic exchange with circulating influenza virus strains. To overcome these difficulties and concerns, currently many other vaccine strategies that elicit antibody response capable of neutralizing diverse HPAI are being developed in various stages, including replication incompetent human adenoviral vector, recombinant fowlpox viruses, recombinant new castle disease viruses, virus like particles (VLP), retroviral pseudotypes, DNA plasmids and recombinant proteins.
Surveillance and early diagnosis of HPAI are essential and demand rapid, sensitive and inexpensive diagnostic tests. It is important to specifically identify H5 subtypes as there is an increased risk for them to become highly pathogenic AIV. Conventional methods including serological methods and RT-PCR are technically demanding and are not suitable for on-site use in field investigations. Rapid and sensitive laboratory and field tests for the diagnosis of H5N1 infection are essential for disease control. In order to develop various immunoassays for AI H5 diagnosis, specific antibodies are essential. The antibodies for virus antigen can establish a series of rapid influenza virus detection tests such as ELISA.
With years of experience in the field of antibody development, Creative Biolabs has successfully developed an advanced AntInfect™ Platform. To overcome poor immunogenicity of HPAI, we have various immunization schemes including recombinant protein, VLP and so on. Our seasoned scientists provide customized antibody production scheme based on your requirements. Except for antibody development, we provide peptide inhibitor development for HPAI. We also have phage display platform which can be used for screening and identifying the virus antigenic epitopes. Please contact us for more information and a detailed quote.
